Kymab
Kymab
Continually improving the best antibody technologies
Human health & social work | United Kingdom of Great Britain and Northern Irela | Access to Information |
Profile Provided By: Company Website
Overview
Kymab is discovering and developing fully human monoclonal antibody therapeutics using our pioneering Kymouse platform. Kymab is building a rich pipeline of assets in four therapeutic spaces immuno oncology inflammation haematology and infectious diseases.
Industry |
Legal Structure |
Operating Status |
Employees |
| Human health & social work | Limited Liability Company | Operating | 51 - 200 employees |
Funding and Financing Rounds
Nov, 2016 / $100M / Series C + / Equity
May, 2014 / $90M / Series B / PRI / Equity
2010 / $30M / Series A / PRI / Equity
Team
Impact
Geographies:
Social Objectives:
Environmental Objectives:
Operational Impact:
- Social Policies and Performance
Impact Reports & Metrics
Offices
Headquarters
Meditrina Babraham Research
Campus Cambridge, CB22 3AT
United Kingdom of Great Britain and Northern Irela